Cases 1 - 10 of 146
Heron Therapeutics, Inc. v. Mylan Pharmaceuticals Inc.
as 1:2024cv00043
Plaintiff:
Heron Therapeutics, Inc.
Defendant:
Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Novo Nordisk Inc. et al v. Mylan Pharmaceuticals Inc.
as 1:2024cv00050
Plaintiff:
Novo Nordisk Inc. and Novo Nordisk A/S
Defendant:
Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Heron Therapeutics, Inc. v. Mylan Pharmaceuticals Inc.
as 1:2023cv01015
Plaintiff:
Heron Therapeutics, Inc.
Defendant:
Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
In Re: Xarelto (Rivaroxaban) ('310) Patent Litigation
as 1:2021md03017
In Re:
Xarelto (Rivaroxaban) ('310) Patent Litigation
Not Classified By Court:
Clerk of MDL Panel, Lupin Limited, Lupin Pharmaceuticals, Inc. and others
Counter Defendant:
Bayer Pharma AG, Bayer AG and Janssen Pharmaceuticals, Inc.
Defendant:
ScieGen Pharmaceuticals, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Mylan Pharmaceuticals Inc. v. Bayer Intellectual Property GMBH et al
as 1:2023cv00556
Plaintiff:
Mylan Pharmaceuticals Inc.
Defendant:
Bayer Intellectual Property GMBH, Bayer AG and Janssen Pharmaceuticals, Inc.
Cause Of Action: 35 U.S.C. § 1 Patent Infringement
In Re: Ozempic (Semaglutide) Patent Litigation
as 1:2022md03038
Not Classified By Court:
Zydus Lifesciences Limited, Ozempic (Semaglutide) Patent Litigation, Novo Nordisk Inc. and others
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Novo Nordisk Inc. et al v. Viatris Inc. et al
as 1:2023cv00101
Plaintiff:
Novo Nordisk Inc. and Novo Nordisk A/S
Defendant:
Viatris Inc. and Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited et al
as 1:2022cv01395
Plaintiff:
Novartis Pharmaceuticals Corporation
Defendant:
Alembic Pharmaceuticals Limited, Alembic Global Holding SA, Alembic Pharmaceuticals, Inc. and others
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Otsuka Pharmaceutical Co., Ltd. et al v. Mylan Laboratories Limited et al
as 1:2022cv01367
Plaintiff:
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S
Defendant:
Mylan Laboratories Limited, Viatris Inc. and Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
In re: Mylan Inc. et al
as 1:2022mc00501
Petitioner:
Mylan Inc. and Mylan Pharmaceuticals Inc.
Respondent:
Somaxon Pharmaceuticals Inc., Procom One Inc., Currax Pharmaceuticals LLC and others
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
